These seven medtech companies aren't just moving the needle, they're getting rid of it all together!
A new study has confirmed the accuracy of the Xpresys Lung 2 test developed by Integrated Diagnostics.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
SQI Diagnostics and Predictive Health bring cardiovascular diagnostics to the forefront with the launch of a serum-based heart attack probability test.
The company says its ImmunoPoC platform can determine in 15 minutes whether a patient has a bacterial or viral infection.
A $45 million funding round completed by DiaCarta to help develop a liquid biopsy test for colorectal cancer is just the latest proof that venture capitalists continue to see liquid biopsy companies as an attractive investment.
Stanford researchers aim to simplify HIV testing and boost early detection rates through a saliva-based test.
A molecular diagnostics company wants to expand its new cartridge-based platform to help orthopedic surgeons make more informed care decisions for patients with a potential joint infection.
Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.
The developer seeks to introduce a low-cost, point-of-care test that could deliver quick results with the help of a smartphone app.
FDA approved Foundation Medicine's companion diagnostic test for solid tumors, making it the first of its kind on the U.S. market.